Suppr超能文献

化学蛋白质组学发现 RNA 甲基转移酶 NSUN2 的同型选择性共价抑制剂。

Chemical Proteomic Discovery of Isotype-Selective Covalent Inhibitors of the RNA Methyltransferase NSUN2.

机构信息

Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550N. Torrey Pines Road, La Jolla, CA-92307, USA.

LMU Munich, Department of Pharmacy, Butenandtstr. 5-13, 81377, Munich, Germany.

出版信息

Angew Chem Int Ed Engl. 2023 Dec 18;62(51):e202311924. doi: 10.1002/anie.202311924. Epub 2023 Nov 14.

Abstract

5-Methylcytosine (m C) is an RNA modification prevalent on tRNAs, where it can protect tRNAs from endonucleolytic cleavage to maintain protein synthesis. The NSUN family (NSUN1-7 in humans) of RNA methyltransferases are capable of installing the methyl group onto the C position of cytosines in RNA. NSUNs are implicated in a wide range of (patho)physiological processes, but selective and cell-active inhibitors of these enzymes are lacking. Here, we use cysteine-directed activity-based protein profiling (ABPP) to discover azetidine acrylamides that act as stereoselective covalent inhibitors of human NSUN2. Despite targeting a conserved catalytic cysteine in the NSUN family, the NSUN2 inhibitors show negligible cross-reactivity with other human NSUNs and exhibit good proteome-wide selectivity. We verify that the azetidine acrylamides inhibit the catalytic activity of recombinant NSUN2, but not NSUN6, and demonstrate that these compounds stereoselectively disrupt NSUN2-tRNA interactions in cancer cells, leading to a global reduction in tRNA m C content. Our findings thus highlight the potential to create isotype-selective and cell-active inhibitors of NSUN2 with covalent chemistry targeting a conserved catalytic cysteine.

摘要

5- 甲基胞嘧啶(mC)是一种普遍存在于 tRNA 上的 RNA 修饰物,它可以保护 tRNA 免受核酸内切酶的切割,从而维持蛋白质合成。RNA 甲基转移酶的 NSUN 家族(人类中的 NSUN1-7)能够将甲基基团安装在 RNA 中胞嘧啶的 C 位置上。NSUNs 参与了广泛的(病理)生理过程,但这些酶的选择性和细胞活性抑制剂仍然缺乏。在这里,我们使用半胱氨酸定向的活性基蛋白谱(ABPP)来发现氮杂环丁烷丙烯酰胺,它是一种对人 NSUN2 具有立体选择性的共价抑制剂。尽管针对 NSUN 家族中保守的催化半胱氨酸,但 NSUN2 抑制剂与其他人类 NSUN 几乎没有交叉反应性,并表现出良好的全蛋白质组选择性。我们验证了氮杂环丁烷丙烯酰胺抑制重组 NSUN2 的催化活性,但不抑制 NSUN6 的活性,并且证明这些化合物在癌细胞中立体选择性地破坏 NSUN2-tRNA 相互作用,导致 tRNA mC 含量的整体降低。因此,我们的研究结果突出了使用靶向保守催化半胱氨酸的共价化学来创建针对 NSUN2 的同工型选择性和细胞活性抑制剂的潜力。

相似文献

引用本文的文献

3
Advancing Covalent Ligand and Drug Discovery beyond Cysteine.超越半胱氨酸推进共价配体与药物发现
Chem Rev. 2025 Jul 23;125(14):6653-6684. doi: 10.1021/acs.chemrev.5c00001. Epub 2025 May 22.
6
RNA modifications in cancer.癌症中的RNA修饰
MedComm (2020). 2025 Jan 10;6(1):e70042. doi: 10.1002/mco2.70042. eCollection 2025 Jan.
10
Ligand discovery by activity-based protein profiling.基于活性的蛋白质谱分析的配体发现。
Cell Chem Biol. 2024 Sep 19;31(9):1636-1651. doi: 10.1016/j.chembiol.2024.08.006.

本文引用的文献

5
Remodeling oncogenic transcriptomes by small molecules targeting NONO.通过靶向 NONO 的小分子重塑致癌转录组。
Nat Chem Biol. 2023 Jul;19(7):825-836. doi: 10.1038/s41589-023-01270-0. Epub 2023 Mar 2.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验